【レポートの概要(一部)】
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 9
2 Ophthalmology Therapeutics in Major Markets – Introduction 10
2.1 Dry Eye Syndrome 10
2.1.1 Classification 10
2.1.2 Symptoms 10
2.1.3 Etiology 10
2.1.4 Pathophysiology 11
2.1.5 Diagnosis 12
2.1.6 Epidemiology 13
2.1.7 Prognosis 14
2.1.8 Treatment Options 14
2.2 Glaucoma 15
2.2.1 Classification 15
2.2.2 Symptoms 16
2.2.3 Etiology 16
2.2.4 Pathophysiology 17
2.2.5 Diagnosis 17
2.2.6 Epidemiology 18
2.2.7 Prognosis 19
2.2.8 Treatment Options 19
3 Ophthalmology Therapeutics in Major Markets – Marketed Products (Global) 21
3.1 Dry Eye Syndrome 21
3.2 Glaucoma 21
3.3 Key Marketed Products 22
3.3.1 Restasis 22
3.3.2 Systane 23
3.3.3 Diquas 24
3.3.4 Mucosta 25
3.3.5 Hyalein 26
3.3.6 Lumigan 27
3.3.7 Alphagan/Alphagan P 28
3.3.8 Simbrinza 29
4 Ophthalmology Therapeutics in Major Markets – Pipeline Analysis 30
4.1 Dry Eye Syndrome Pipeline 30
4.1.1 Overall Pipeline 30
4.1.2 Pipeline Analysis by Molecule Type 32
4.1.3 Pipeline Analysis by Mechanism of Action 34
4.2 Glaucoma Pipeline 36
4.2.1 Overall Pipeline 36
4.2.2 Pipeline Analysis by Molecule Type 38
4.2.3 Pipeline Analysis by Mechanism of Action 39
4.3 Promising Drug Candidates in the Pipeline 41
4.3.1 CF-101 41
4.3.2 MIM-D3 41
4.3.3 SAR-1118 41
4.3.4 DE-111 42
5 Ophthalmology Therapeutics in Major Markets – Market Forecast to 2019 43
5.1 Major Markets 43
5.1.1 Treatment Usage Patterns 43
5.1.2 Annual Cost of Therapy 43
5.1.3 Market Size 43
5.2 The US 45
5.2.1 Treatment Usage Patterns 45
5.2.2 Annual Cost of Therapy 45
5.2.3 Market Size 45
5.3 Top Five European Countries 47
5.3.1 Treatment Usage Patterns 47
5.3.2 Annual Cost of Therapy 47
5.3.3 Market Size 47
5.4 Canada 49
5.4.1 Treatment Usage Patterns 49
5.4.2 Annual Cost of Therapy 49
5.4.3 Market Size 49
5.5 Japan 51
5.5.1 Treatment Usage Patterns 51
5.5.2 Annual Cost of Therapy 51
5.5.3 Market Size 51
5.6 Drivers and Barriers 53
5.6.1 Drivers 53
5.6.2 Barriers 53
6 Ophthalmology Therapeutics in Major Markets – Deals and Strategic Consolidations (Global) 55
6.1 Deals Analysis 55
6.2 Major Co-Development Deals 57
6.2.1 NicOx Signs Research Agreement with Pfizer 58
6.2.2 Acucela Enters into Co-development Agreement with Otsuka Pharma for Rebamipide 58
6.2.3 Akorn Enters into Agreement with Azad Pharma 58
6.3 Major Licensing Deals 59
6.3.1 NicOx Enters into Worldwide Licensing Agreement with Bausch & Lomb 60
6.3.2 Quark Pharma Amends Licensing Agreement with Pfizer for PF-655 60
6.3.3 Asterand Enters into Licensing Agreement with Allergan 60
7 Ophthalmology Therapeutics in Major Markets – Appendix 61
7.1 All Pipeline Drugs by Phase 61
7.1.1 Discovery 61
7.1.2 Preclinical 61
7.1.3 IND/CTA-filed 63
7.1.4 Phase I 63
7.1.5 Phase II 64
7.1.6 Phase III 65
7.1.7 Pre-registration 65
7.1.8 Undisclosed 66
7.2 Market Forecasts to 2019 66
7.2.1 Major Markets 66
7.2.2 The US 67
7.2.3 The UK 67
7.2.4 France 68
7.2.5 Germany 69
7.2.6 Italy 69
7.2.7 Spain 70
7.2.8 Canada 71
7.2.9 Japan 71
7.3 Market Definitions 72
7.4 Abbreviations 72
7.5 Sources 74
7.6 Research Methodology 75
7.6.1 Coverage 76
7.6.2 Secondary Research 76
7.6.3 Primary Research 76
7.6.4 Therapeutic Landscape 77
7.6.5 Geographical Landscape 80
7.6.6 Pipeline Analysis 80
7.7 Expert Panel Validation 80
7.8 Contact Us 80
7.9 Disclaimer 80
【レポート販売概要】
■ タイトル:Ophthalmology Therapeutics in Major Developed Markets to 2019 – New Drug Approvals and Promising Pipeline to Trigger Shift in Treatment Paradigm to Combination Therapies■ 発行日:2013年11月30日
■ 調査会社:GBI Research
■ 商品コード:GBIR403170047
■ 調査対象地域:グローバル
- DCP Midstream, LLC:石油・ガスバリューチェーン分析レポート2013DCP Midstream, LLC Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "DCP Midstream, LLC" Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “DCP Midstream, LLC”. The report provides key information relating to oil and gas assets of the company along with its operations across the value chain. The report examines t …
- 通信設備用電源システムの世界市場:DCシステム、ACシステムAbout telecom power systems Telecom operators require power systems to monitor and control operations and to provide uninterruptible services to subscribers. These power systems consist of a set of individual systems such as converters, distribution systems, controllers, and backup systems, which hold different technical specifications. The main applications of these systems can be found in wirele …
- ポリアルキレングリコールの世界市場:ポリエチレングリコール(PEG) 、ポリプロピレングリコール(PPG)The global PAGs market was estimated to be worth USD 1.33 Billion in 2014 and is projected to reach USD 2.62 Billion by 2020, at a CAGR of 11.7% between 2015 and 2020. This high growth of the market is owed to the increasing demand from end-use industries in the U.S., Germany, France, China, India, and Japan. The increased usage of PAGs in a variety of applications is also one of the key factor dr …
- SoI(システムオヴインサイト)の世界市場予測(~2024年)The global system of insight market size to grow at a Compound Annual Growth Rate (CAGR) of 22.2% during the forecast periodThe global system of insight market size is expected to grow from USD 1.2 billion in 2019 to USD 3.4 billion by 2024, at a Compound Annual Growth Rate (CAGR) of 22.2% during the forecast period. The major factors expected to drive the growth of the system of insight market in …
- ADME毒性検査の世界市場:生体内検査、試験管内検査About ADME-Toxicology Testing ADME-toxicology testing is the evaluation of the metabolism of a drug molecule and its toxicity in an organism. ADME describes the pharmacological changes of a drug inside a living organism. These studies are traditionally carried out in vivo or in vitro in a controlled laboratory environment. Technavio's analysts forecast the global ADME-toxicology testing market to …
- Regency Energy Partners LP:石油・ガスバリューチェーン分析レポート2013Regency Energy Partners LP Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "Regency Energy Partners LP" Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “Regency Energy Partners LP”. The report provides key information relating to oil and gas assets of the company along with its operations across the value chai …
- リヨセル繊維の世界市場2015-2019About lyocell fiber Lyocell is a man-made fiber that is derived from cellulose. It is manufactured through a solvent spinning technique by closed loop method, where cellulose undergoes a chemical change. Lyocell fibers are significantly used in textiles and are made from wood pulp. Lyocell fiber is the strongest cellulose fiber when dry and known for its durable property. Technavio's analysts fore …
- 術後の吐き気および嘔吐(Post Operative Nausea And Vomiting):世界の治験レビュー(2015年上半期版)Post Operative Nausea And Vomiting Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Post Operative Nausea And Vomiting Global Clinical Trials Review, H1, 2015" provides data on the Post Operative Nausea And Vomiting clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Post Operative Nausea And Vomiting. …
- 副鼻腔拡張装置の世界市場:製品別(バルーン式副鼻腔拡張装置、ステント、内視鏡、ハンドヘルド器具)、手術法別(単独(スタンドアロン)、併用(ハイブリッド))、患者タイプ別(成人、小児)、患者の医療環境別(耳鼻咽喉科、診療所、病院、通院外科診療所)、地域別予測Global Sinus dilation devices Market to reach USD 3.4 billion by 2025. Global Sinus dilation devices Market valued approximately USD 1.5 billion in 2016 is anticipated to grow with a healthy growth rate of more than 9.5% over the forecast period 2017-2025. Key factors which gives growth to the Sinus dilation devices market are growing preference for minimally invasive procedures, benefits of ballo …
- バイオケトンの世界市場:バイオMEK、バイオPEEK、バイオ・アセトンAbout Bio-ketones market Bio-ketones are a type of organic compounds which possess important physiological properties which are produced from bio-based raw materials, herby making it environment-friendly. Bio-ketones are majorly used as solvents in the paint and coating sector, as preservatives, and in hydraulic fluids. TechNavio's analysts forecast the Global Bio-ketones Market to grow at a CAGR …
- 副鼻腔炎(Sinusitis):治療薬開発パイプライン動向(2015年上半期版)Sinusitis - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Sinusitis - Pipeline Review, H1 2015’, provides an overview of the Sinusitis’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Sinusitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of admin …
- 下肢の筋痙縮治療のグローバル臨床試験動向(2014年H2)Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014" provides data on the Lower Limb Muscle Spasticity clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lower Limb Muscle Spasticity. It includes an overview …
- 卵管がん(Fallopian Tube Cancer):治療薬開発パイプライン動向(2015年上半期版)Fallopian Tube Cancer - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Fallopian Tube Cancer - Pipeline Review, H1 2015’, provides an overview of the Fallopian Tube Cancer’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug t …
- 免疫組織化学の世界市場予測(~2021):抗体、試薬、キット、スライド染色装置、組織マイクロアレイThe immunohistochemistry market is projected to reach USD 2.12 Billion by 2021, growing at a CAGR of 7.3% during the forecast period. Rising geriatric population, growing prevalence of chronic diseases, rapid technological developments in the IVD industry, and increasing healthcare spending are expected to fuel the growth of this market in the coming years. However, rapid growth in the developing …
- BAY 94-9027 (Hemophilia A and B):市場予測と分析(~2022)BAY 94-9027 (Hemophilia A and B) - Forecast and Market Analysis to 2022 Summary The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing thr …